stock upgrade
Twist Bioscience Shares Upgraded to Outperform by Evercore ISI
Evercore cited the synthetic DNA maker's response to a recent report from a short seller that dragged down its shares toward the end of 2022.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
Illumina Upgraded to Outperform by Evercore ISI
The stock upgrade comes right before an event where Illumina has said it will provide information on a new sequencing-by-synthesis chemistry.
Illumina, Belgium Genetic Centers Partner on WGS-Based Diagnostics; Evercore Upgrades Illumina Shares
The San Diego-based sequencing technology firm is also launching noninvasive prenatal genetic testing on the VeriSeq v2 platform in Thailand.
Illumina Upgraded to Buy by Canaccord Genuity
Analyst Max Masucci told investors he believes the stock is worth owning now, regardless of uncertainty surrounding Illumina's plans to acquire Grail.
Dec 22, 2020
Illumina Upgraded to Overweight by Piper Sandler
Oct 15, 2019
Pacific Biosciences Stock Upgraded by Piper Jaffray
Jan 4, 2019
Cowen Upgrades Myriad Genetics Stock
Mar 8, 2018
Raymond James Upgrades Quidel to Strong Buy
Jan 2, 2018
Wells Fargo Upgrades Illumina to Outperform
Dec 11, 2017
Cowen Upgrades Hologic to Outperform
Apr 21, 2017
Raymond James Upgrades Quest to Outperform
Mar 7, 2017
Janney Upgrades Foundation Medicine to Neutral
Feb 27, 2017
Evercore ISI Upgrades Illumina Shares to Buy
Jan 4, 2017
Barclays Upgrades Agilent, Downgrades Bruker
Nov 29, 2016